Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics
Stocks in this Quantisnow insightHealth Care
Historical context for HYPR
Across the 10 sessions after earlier HYPR headlines, the stock closed higher 6 times and lower 3 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HYPR | SPY |
|---|---|---|---|
| Jan 15, 2026 | Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents | -1.6% | +0.3% |
| Jan 12, 2026 | Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results | +1.0% | +0.2% |
| Jan 6, 2026 | Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care | +3.0% | +0.6% |
| Dec 17, 2025 | Hyperfine Announces Regulatory Approval of the Swoop® System in India | +0.6% | -1.1% |
| Dec 15, 2025 | Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System | -6.8% | -0.2% |
| Nov 21, 2025 | Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference | +2.4% | +1.0% |
Quantisnow market dataNASDAQ
HYPR
Hyperfine Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Listed since
- 2021
Get push alerts for HYPR
Full HYPR profile on Quantisnow Follow HYPR and get a push notification the moment its next story breaks.